Cholinesterases and Cholinesterase Inhibitors

Author(s): Sarka Stepankova, Karel Komers

Journal Name: Current Enzyme Inhibition

Volume 4 , Issue 4 , 2008

Become EABM
Become Reviewer
Call for Editor


Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.

Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [160 - 171]
Pages: 12
DOI: 10.2174/157340808786733631
Price: $65

Article Metrics

PDF: 6